Are you Dr. Malka?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 104 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
7539 Medical Dr
Hudson, FL 34667Phone+1 727-869-2115Fax+1 727-863-6167
Summary
- Dr. David Malka, MD is a board certified neurologist in Hudson, Florida. He is currently licensed to practice medicine in Florida. He is affiliated with HCA Florida Bayonet Point Hospital, Morton Plant North Bay Hospital, and Bayfront Health Spring Hill.
Education & Training
University of South Florida MorsaniResidency, Neurology, 1991 - 1994- University of South Florida MorsaniInternship, Internal Medicine, 1990 - 1991
Rutgers New Jersey Medical SchoolClass of 1990
Certifications & Licensure
FL State Medical License 1991 - 2026- American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification Practice Fusion EHR, Practice Fusion, Inc., 2011-2013
Clinical Trials
- Leucovorin, Fluorouracil, Cetuximab, and Oxaliplatin in Treating Patients With Stage IV Colorectal Cancer and Liver Metastases That Cannot Be Removed by Surgery Start of enrollment: 2006 Oct 01
- Impact of Immunoscore Colon Test on Adjuvant Therapeutic Strategy in Non-Metastatic Colon Cancer Start of enrollment: 2019 May 01
Publications & Presentations
PubMed
- 11 citationsIndividual patient data meta-analysis of adjuvant gemcitabine-based chemotherapy for biliary tract cancer: combined analysis of the BCAT and PRODIGE-12 studies.Julien Edeline, Satoshi Hirano, Aurélie Bertaut, Masaru Konishi, Meher Benabdelghani
European Journal of Cancer. 2022-03-01 - 51 citationsImmune scores in colorectal cancer: Where are we?David Malka, Astrid Lièvre, Thierry André, Julien Taieb, Michel Ducreux
European Journal of Cancer. 2020-10-16 - 28 citationsFOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA)...David Malka, Eric Francois, Frédérique Penault-Llorca, Florence Castan, Olivier Bouché
European Journal of Cancer. 2019-07-01
Press Mentions
Adjuvant Capecitabine New Standard for Biliary Tract CancerMarch 31st, 2019
